Lantus
Sanofi builds case for Toujeo in younger type 1 diabetics
Phil Taylor
Diabetes, insulin, Lantus, Sanofi, Toujeo, type 1 diabetes
0 Comment
X
Sanofi builds case for Toujeo in younger type 1 diabetics
https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Mylan’s Lantus biosimilar held up by manufacturing issue
Phil Taylor
Biocon, biosimilar, Diabetes, insulin, Lantus, Mylan, Sanofi
0 Comment
X
Mylan’s Lantus biosimilar held up by manufacturing issue
https://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Sanofi beats expectations, driven by rare diseases and vaccines
Richard Staines
Dupixent, Genzyme, Lantus, Sanofi, Sanofi-Pasteur
0 Comment
But sales of key insulin fall amid biosimilar competition.
X
Sanofi beats expectations, driven by rare diseases and vaccines
https://pharmaphorum.com/news/sanofi-beats-expectations-driven-rare-diseases-vaccines/